MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
2.625
+0.065
+2.54%
Opening 11:07 12/05 EST
OPEN
2.570
PREV CLOSE
2.560
HIGH
2.700
LOW
2.530
VOLUME
846.89K
TURNOVER
--
52 WEEK HIGH
5.46
52 WEEK LOW
0.9857
MARKET CAP
252.70M
P/E (TTM)
-1.0479
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CABA last week (1124-1128)?
Weekly Report · 4d ago
SA Quant ranks Goldman's small-cap stocks with largest short interest
Seeking Alpha · 11/26 20:13
Weekly Report: what happened at CABA last week (1117-1121)?
Weekly Report · 11/24 09:11
Jefferies Sticks to Their Buy Rating for Cabaletta Bio (CABA)
TipRanks · 11/18 14:25
Weekly Report: what happened at CABA last week (1110-1114)?
Weekly Report · 11/17 09:11
Guggenheim Sticks to Its Buy Rating for Cabaletta Bio (CABA)
TipRanks · 11/14 08:15
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
Seeking Alpha · 11/14 07:24
Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating
TipRanks · 11/11 12:36
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.